# A threshold method for immunological correlates of protection.

**ABSTRACT** BACKGROUND: Immunological correlates of protection are biological markers such as disease-specific antibodies which correlate with protection against disease and which are measurable with immunological assays. It is common in vaccine research and in setting immunization policy to rely on threshold values for the correlate where the accepted threshold differentiates between individuals who are considered to be protected against disease and those who are susceptible. Examples where thresholds are used include development of a new generation 13-valent pneumococcal conjugate vaccine which was required in clinical trials to meet accepted thresholds for the older 7-valent vaccine, and public health decision making on vaccination policy based on long-term maintenance of protective thresholds for Hepatitis A, rubella, measles, Japanese encephalitis and others. Despite widespread use of such thresholds in vaccine policy and research, few statistical approaches have been formally developed which specifically incorporate a threshold parameter in order to estimate the value of the protective threshold from data. METHODS: We propose a 3-parameter statistical model called the a:b model which incorporates parameters for a threshold and constant but different infection probabilities below and above the threshold estimated using profile likelihood or least squares methods. Evaluation of the estimated threshold can be performed by a significance test for the existence of a threshold using a modified likelihood ratio test which follows a chi-squared distribution with 3 degrees of freedom, and confidence intervals for the threshold can be obtained by bootstrapping. The model also permits assessment of relative risk of infection in patients achieving the threshold or not. Goodness-of-fit of the a:b model may be assessed using the Hosmer-Lemeshow approach. The model is applied to 15 datasets from published clinical trials on pertussis, respiratory syncytial virus and varicella. RESULTS: Highly significant thresholds with p-values less than 0.01 were found for 13 of the 15 datasets. Considerable variability was seen in the widths of confidence intervals. Relative risks indicated around 70% or better protection in 11 datasets and relevance of the estimated threshold to imply strong protection. Goodness-of-fit was generally acceptable. CONCLUSIONS: The a:b model offers a formal statistical method of estimation of thresholds differentiating susceptible from protected individuals which has previously depended on putative statements based on visual inspection of data.

**0**Bookmarks

**·**

**121**Views

- Citations (57)
- Cited In (0)

- [Show abstract] [Hide abstract]

**ABSTRACT:**Because of concern about safety and efficacy, no pertussis vaccine has been included in the vaccination program in Sweden since 1979. To provide data that might permit the reintroduction of a pertussis vaccine, we conducted a placebo-controlled trial of two acellular and one whole-cell pertussis vaccines. After informed consent was obtained, 9829 children born in 1992 were randomly assigned to receive one of four vaccines: a two-component acellular diphtheria-tetanus-pertussis (DTP) vaccine (2566 children), a five-component acellular DTP vaccine (2587 children), a whole-cell DTP vaccine licensed in the United States (2102 children), or (as a control) a vaccine containing diphtheria and tetanus toxoids (DT) alone (2574 children). The vaccines were given at 2, 4, and 6 months of age, and the children were then followed for signs of pertussis for an additional 2 years (to a mean age of 21/2 years). The whole-cell vaccine was associated with significantly higher rates of protracted crying, cyanosis, fever, and local reactions than the other three vaccines. The rates of adverse events were similar for the acellular vaccines and the control DT vaccine. After three doses, the efficacy of the vaccines with respect to pertussis linked to a laboratory-confirmed case of pertussis or contact with an infected household member with paroxysmal cough for > or = 21 days was 58.9 percent for the two-component vaccine (95 percent confidence interval, 50.9 to 65.9 percent), 85.2 percent for the five-component vaccine (95 percent confidence interval, 80.6 to 88.8 percent), and 48.3 percent for the whole-cell vaccine (95 percent confidence interval, 37.0 to 57.6 percent). The five-component acellular pertussis vaccine we evaluated can be recommended for general use, since it has a favorable safety profile and confers sustained protection against pertussis. The two-component acellular vaccine and the whole-cell vaccine were less efficacious.New England Journal of Medicine 03/1996; 334(6):349-55. · 54.42 Impact Factor - [Show abstract] [Hide abstract]

**ABSTRACT:**To determine if respiratory syncytial virus (RSV) specific, serum antibody titers correlate with protection against RSV associated-hospitalization at all ages. Participants who were enrolled in a trial to determine the frequency of specific virus infections associated with hospitalization [J. Am. Med. Assoc. 283 (2000) 499] were included in our analysis if they were enrolled from July 1991 to June 1993, had a culture for virus isolation, and provided blood samples at hospitalization and 14-60 days later. RSV infection was defined by a positive culture and/or serology. Microneutralization, ELISA to the fusion (F) protein and Western blot were the serological assays that were used to determine correlates of immunity. One hundred and seventy-five individuals, 1 month to 89 years old, out of 538 patients hospitalized with an acute respiratory infection met the criteria for analysis. RSV associated-hospitalization occurred in 11 (40.7%) of 27 infants (<1 year), 8 (38.1%) of 21 young children (1 to <5 years), and 15 (11.8%) of 127 children and adults (> or =5 years). At the time of hospitalization, geometric mean neutralizing antibody titers (log(2)) to RSV/A and RSV/B, and geometric mean binding antibody titer (log(2)) to F protein were significantly higher in patients with non-RSV associated-hospitalization compared to those with RSV associated-hospitalization (RSV/A: 7.9 versus 6.1, P<0.001; RSV/B: 9.4 versus 7.3, P<0.001; ELISA-F, 13.9 versus 12.6, P=0.01). For every 1 log(2) increase in titer of neutralizing antibodies to RSV/A and RSV/B, and binding antibody to F protein there was a significant increase in the likelihood of not having an RSV associated-hospitalization by 22.3, 25, and 24.4% respectively. A minimal protective threshold titer of > or =6.0 (odds ratio 3.5; 95% CI 1.4-9.1) and > or =8.0 log(2) (odds ratio 2.9; 95% CI 1.1-7.7) against RSV associated-hospitalization was established for neutralizing antibodies to RSV/A and RSV/B; a threshold titer could not be established for binding antibody to F protein. Participants with naturally acquired serum neutralizing antibody levels at least equal to the minimal protective threshold titer were approximately three times more likely not to have an RSV associated-hospitalization. We speculate that achieving a minimal protective threshold antibody titer through active immunization will significantly reduce RSV associated-hospitalization among all ages.Vaccine 08/2003; 21(24):3479-82. · 3.49 Impact Factor - C J White, B J Kuter, A Ngai, C S Hildebrand, K L Isganitis, C M Patterson, A Capra, W J Miller, D L Krah, P J Provost[Show abstract] [Hide abstract]

**ABSTRACT:**Four thousand forty-two healthy children and adolescents, ages 12 months to 17 years, were vaccinated with a single dose of live attenuated varicella vaccine (VARIVAX; Merck Sharp and Dohme Research Laboratories) containing approximately 1000 to 1625 plaque-forming units/dose during clinical trials conducted from 1987 to 1989. Clinical follow-up of vaccinees revealed that 2.1 and 2.4% of vaccinees developed modified cases of varicella in the first and second years, respectively, after vaccination. Most of those who developed varicella postvaccination had an attenuated illness, characterized by fewer lesions and a lower incidence of fever (greater than or equal to 100 degrees F, oral) than after natural infection. The likelihood of developing varicella postvaccination decreased (P less than 0.0001) as the 6-week postvaccination glycoprotein-based enzyme-linked immunosorbent assay titer increased. In addition the number of lesions in these cases tended to decrease (P = 0.07 for Year 1 and P = 0.02 for Year 2) as the 6-week glycoprotein-based enzyme-linked immunosorbent assay titer increased. Thus the 6-week postvaccination glycoprotein-based enzyme-linked immunosorbent assay titer can be used as a surrogate marker for protection from natural disease.The Pediatric Infectious Disease Journal 02/1992; 11(1):19-23. · 3.14 Impact Factor

Page 1

RESEARCH ARTICLE Open Access

A threshold method for immunological correlates

of protection

Xuan Chen1, Fabrice Bailleux2, Kamal Desai3*, Li Qin4,5and Andrew J Dunning6

Abstract

Background: Immunological correlates of protection are biological markers such as disease-specific antibodies which

correlate with protection against disease and which are measurable with immunological assays. It is common in vaccine

research and in setting immunization policy to rely on threshold values for the correlate where the accepted threshold

differentiates between individuals who are considered to be protected against disease and those who are susceptible.

Examples where thresholds are used include development of a new generation 13-valent pneumococcal conjugate

vaccine which was required in clinical trials to meet accepted thresholds for the older 7-valent vaccine, and public health

decision making on vaccination policy based on long-term maintenance of protective thresholds for Hepatitis A, rubella,

measles, Japanese encephalitis and others. Despite widespread use of such thresholds in vaccine policy and research,

few statistical approaches have been formally developed which specifically incorporate a threshold parameter in order to

estimate the value of the protective threshold from data.

Methods: We propose a 3-parameter statistical model called the a:b model which incorporates parameters for a

threshold and constant but different infection probabilities below and above the threshold estimated using profile

likelihood or least squares methods. Evaluation of the estimated threshold can be performed by a significance test for

the existence of a threshold using a modified likelihood ratio test which follows a chi-squared distribution with

3 degrees of freedom, and confidence intervals for the threshold can be obtained by bootstrapping. The model also

permits assessment of relative risk of infection in patients achieving the threshold or not. Goodness-of-fit of the a:b

model may be assessed using the Hosmer-Lemeshow approach. The model is applied to 15 datasets from published

clinical trials on pertussis, respiratory syncytial virus and varicella.

Results: Highly significant thresholds with p-values less than 0.01 were found for 13 of the 15 datasets. Considerable

variability was seen in the widths of confidence intervals. Relative risks indicated around 70% or better protection in 11

datasets and relevance of the estimated threshold to imply strong protection. Goodness-of-fit was generally acceptable.

Conclusions: The a:b model offers a formal statistical method of estimation of thresholds differentiating susceptible

from protected individuals which has previously depended on putative statements based on visual inspection of data.

Keywords: Vaccine, Correlate of protection, Protective threshold, Immunological assay

Background

Immunological correlates of protection are measurable

and specific biological markers which correlate with pro-

tection against disease caused by an infectious pathogen.

The markers used are most often pathogen-specific neu-

tralizing antibodies whose concentration can be measured

with biological assays [1]. Researchers and agencies respon-

sible for immunization recommendations, such as the US

Advisory Committee for Immunization Practices and the

World Health Organization, rely on established threshold

values for the immunological correlate of protection where

the accepted threshold differentiates between individuals

who are considered to be immunologically protected

against disease and those who are susceptible [2,3]. When

it is strongly correlated with protection with a recognized

threshold, it can be called an absolute correlate [4].

Uses for the established threshold for a correlate of

protection are numerous. For instance, where the corre-

late has been established for a vaccine that has already

* Correspondence: kamal.desai@unitedbiosource.com

3United Biosource Corporation, London, UK

Full list of author information is available at the end of the article

© 2013 Chen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative

Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and

reproduction in any medium, provided the original work is properly cited.

Chen et al. BMC Medical Research Methodology 2013, 13:29

http://www.biomedcentral.com/1471-2288/13/29

Page 2

demonstrated clinical efficacy against disease, the correl-

ate simplifies study of the vaccine in new populations,

age- or risk-groups by permitting clinical trials to be

conducted with immunogenicity endpoints and avoiding

large-scale efficacy trials. The US Food and Drug Ad-

ministration (FDA) offers accelerated approval when

there is a correlate (FDA prefers the term “surrogate”)

that is considered “reasonably likely” to predict clinical

benefits [5]. Other uses include the study of immuno-

genicity for co-administration with other vaccines,

comparisons of combination vaccines to individual com-

ponent vaccines and assessment of the duration of pro-

tection. The established correlate of protection also

permits comparisons of new generation vaccines to older

ones. For completely novel vaccines, the demonstration

of a candidate immunologic correlate is becoming a sec-

ondary yet fundamental objective in clinical trials and

epidemiological studies. This is encouraged by agencies

such as the US FDA Center for Biologics Evaluation and

Research and is one of the Grand Challenges in Global

Health [6]. Thus the accurate identification of protective

threshold levels clearly has important implications for

the licensure of vaccines and for immunization policy.

Research in correlates of protection is multidisciplinary.

As a consequence, terminology used has been inconsist-

ent and sometimes confusing. There have been recent

efforts to harmonize the terminology employed and to

link this to a hierarchy of statistical evidence for the

demonstration of a correlate [4,7,8]. In addition the ter-

minology has been further refined by introducing the

termsmechanisticand nonmechanistic

whether the correlate of protection is causal or not [9].

We will here for convenience use the term ‘correlate of

protection’ in the broadest sense, to include immuno-

logical assays that have been consistently shown to cor-

relate with risk of disease, assays that have been shown

to be causally associated with protection, or specific

threshold values of assays which have been accepted or

proposed as differentiating susceptible from protected

individuals. We also use the term ‘protective threshold’ to

refer to an assay value for the correlate that distinguishes

protected and unprotected individuals when the relation-

ship between the correlate and protection can be reliably

and usefully summarized with a single threshold value.

However, individual variability means that at any thresh-

old value some above will be susceptible and some below

protected, and ‘protective threshold’ is not intended to

imply any particular level of protection, and specifically is

not intended to imply complete protection or ‘sterile im-

munity’. ‘Assay value’ and ‘titer’ are used interchangeably,

according to context. A general opinion is emerging that

improvement in statistical methods is needed [10,11] for

identifying correlates of protection, but opinions vary on

the appropriate statistical methodology. Methods and

to address

study designs have varied historically and across disease

areas resulting in different standards of data quality and

statistical methods to establish correlates of protection

and their threshold values.

For older vaccines, the protective immunological

thresholds have often been determined based on obser-

vational data, which was sometimes conveniently avail-

able or opportunistic. For example, Björkholm et al.

measured diphtheria antitoxin titers in 44 individuals ad-

mitted to hospital during a diphtheria epidemic among

alcoholics in Sweden and observed that 7 of 10 patients

who had diphtheria antitoxin titers<0.01 IU/ml died or

showed neurological complications, whereas 33 out of

34 diphtheria carriers with antitoxin titers ≥ 0.16 IU/ml

remained symptom-free [12]. Further in vitro studies

suggested that titers between 0.01 and 0.09 IU/ml may

be regarded as giving basic immunity, whereas a higher

titer of 0.1 IU/ml was considered fully protective [13].

When an outbreak of measles occurred among students

in a dormitory at Boston University, Chen et al. obtained

permission to assay samples of blood donations made

shortly before the start of the outbreak and compared

their antibody concentrations with the occurrences of

measles [14]. Of 9 donors with detectable pre-exposure

plaque reduction neutralization titer less than or equal

to 120, 8 met the clinical criteria for measles compared

with none of 71 with pre-exposure titers greater than

120. Similarly, Neumann collected sera from 238 high

school students on Prince Edward Island before a mea-

sles epidemic sweeping the rest of Canada reached the

island to compare infection rates by titer [15].

An early study by Goldschneider et al. established a

protective threshold for meningococcal C disease based

on serum bactericidal assay [16]. American army

recruits provided blood samples for assaying at the

start of basic training, and disease occurred in only 1%

of individuals who had titers greater than 4 of SBA at

recruitment compared to 22% of those who had less than

4. This was further confirmed by a population study that

demonstrated an inverse relationship between disease in-

cidence and the presence of SBA titers.

These early studies and others [17] selected protective

thresholds based on inspection of disease rates observed

in discrete intervals of assay values with confidence

limits never reported. Siber provides an in-depth discus-

sion of this approach [18] and introduces the idea of

titer-specific degrees of protection.

For newer vaccines, clinical trials or observational

studies specifically incorporate immunological data col-

lection to identify potential thresholds, and statistical

approaches have accordingly been developed for this pur-

pose. For instance, in the Chang-Kohberger method data

from three double-blind controlled trials in Northern

Californian, American Indian and South African infants

Chen et al. BMC Medical Research Methodology 2013, 13:29

http://www.biomedcentral.com/1471-2288/13/29

Page 2 of 10

Page 3

were pooled in a meta-analysis to derive a protective

threshold of 0.35 μg/ml for anticapsular antibodies for a

7-valent pneumococcal conjugate vaccine against inva-

sive pneumococcal disease [19,20]. The statistical method

equates relative risk of invasive pneumococcal disease

between vaccine and control groups to the relative

risk of having antibody concentration below the pro-

tective threshold, and the protective threshold is then

found from cumulative distribution curves of the anti-

body concentrations of the vaccinated group and the

control groups. The threshold has been endorsed by a

WHO Working Group and has subsequently been used

to develop and license a newer generation 13-valent

vaccine [21].

It was essentially this same method that was employed

by Andrews et al. to derive a threshold for a correlate of

protection following meningococcal C vaccination [22].

The two modern examples for pneumococcal and

meningococcal C vaccines that employed the Chang-

Kohberger method, however, required an estimate of

vaccine efficacy based on a clinical endpoint before the

method could be used.

Few other statistical methods exist for identifying a

threshold. The idea of estimating separate disease prob-

abilities a and b below and above a threshold has been

proposed by Siber et al. but no actual model was

developed to estimate the threshold [20].

Other statistical approaches have focused on continu-

ous models, which do not explicitly model a threshold.

Logistic regression has frequently been used [23-28];

other continuous models have included proportional

hazards [29] and Bayesian generalized linear models

[30]. Chan compared Weibull, log-normal, log-logistic

and piecewise exponential models applied to varicella

data [31]. A limitation of such models is that they can-

not separate exposure to disease from protection against

disease given exposure, the latter being the relationship

of interest. A scaled logit model which separates expos-

ure and protection where protection is a continuous

function of assay value has been proposed [32]. The

scaled logit model was illustrated with data from the

German pertussis efficacy trial data [27] and has been

used to describe the relationship between influenza assay

titers and protection against influenza [33-35]. However,

these approaches do not explicitly allow identification of

a single threshold value.

Thus despite the fundamental reliance on thresholds in

vaccine science and immunization policy, previous statis-

tical models have not specifically incorporated a thresh-

old parameter for estimation or testing. In this paper, we

propose a statistical approach based on the suggestion in

Siber et al. [20] for estimating and testing the threshold

of an immunologic correlate by incorporating a threshold

parameter, which is estimable by profile likelihood or

least squares methods and can be tested based on a

modified likelihood approach. The model does not re-

quire prior vaccination history to estimate the threshold

and is therefore applicable to observational as well as

randomized trial data. In addition to the threshold par-

ameter the model contains two parameters for constant

but different infection probabilities below and above the

threshold and can be viewed as a step-shaped function

where the step corresponds to the threshold. The model

will be referred to as the a:b model.

Methods

Model specification and fitting

For subjects i=1,...,n, let ti represent the immuno-

logical assay value for subject i (typically immunological

assay valuesare log-transformed

calculations). Let Yi=1 represent the event that subject i

subsequently develops disease, and Yi= 0 the event that

they do not and τ represent a threshold differentiating

susceptible from protected individuals. Then the model

is given by

beforemaking

P Yi¼ 1

P Yi¼ 0

ð

ð

Þ ¼ a ? 1 ti< τ

Þ ¼ 1 ? a ? 1 ti< τ

ð Þ þ b ? 1 ti> τ

Þ ? b ? 1 ti> τ

ðÞ

ððÞ

where a, b represent the probability of disease below

and above the threshold respectively and 1(·) takes the

value 1 when its argument in parenthesis is true or 0

otherwise.Since theassay

observations of a continuous variable, and the likelihood

and residual sum of squares are each constant at any

value of τ falling between a pair of adjacent observed

discrete assay values, a reasonable choice for the candi-

date values of τ are the geometric means of adjacent

pairs of ordered observed assay values (i.e. the arithmetic

mean of log-transformed assay values). The log of the

likelihood for the model is given by

valuesti

arediscrete

l a;b;τ

ð Þ ¼

X

þ 1 ? yi

n

i¼1

yilog α ? 1 ti< τ

ð Þ þ b ? 1 t1> τ

ðÞ½?

ðÞlog 1 ? α ? 1 ti< τ

ð Þ ? b ? 1 ti> τ

ðÞ½?

To fit the models, closed form expressions may be

derived by maximum likelihood or least squares for

estimators of the parameters a, b but not for τ. The

estimators for a, b remain as functions of τ. Following

the profile likelihood or least squares approach, the opti-

mal value of τ may be found by proceeding through the

candidate values, estimating the other parameters and

the likelihood or sum of squared errors at each value.

The value of τ that maximizes the likelihood or

minimizes the sum of squares is the estimate for τ. The

derivation of the least squares and maximum likelihood

estimators of a, b is shown in the Additional file 1.

Chen et al. BMC Medical Research Methodology 2013, 13:29

http://www.biomedcentral.com/1471-2288/13/29

Page 3 of 10

Page 4

A previous method which seeks to identify a cut

point is the maximal chi-square proposed by Miller

[36]. Here a continuous variable which is predictive of

a clinical outcome is dichotomized using a cut point

with cases and non-cases displayed in a 2×2 table. The

optimal cut point corresponds to the maximal chi-

square associated with the 2×2 table. It can be shown

that the estimated threshold τ selected by least squares

in the a:b model corresponds to the optimal cut point

obtained via the maximal chi-square method; a proof is

given in the Additional file 1.

Testing for the existence of a threshold

Note that in the absence of a threshold the model

reduces to a constant probability of infection independ-

ent of assay value. Thus to test for the existence of a

threshold, the likelihood of the a:b model including the

threshold τ and different infection probabilities a, b

below and above the threshold is compared to the likeli-

hood of a model without a threshold but a constant in-

fection probability a’ for all assay values. The test

statistic is the difference of minus 2 times the likelihood

of the models:

D ¼ ?2l a;b;τ

However, the additional requirement a>b is imposed

by requiring D = 0 when a<b so the modified test

statistic is

ðÞ þ 2l a0

ð Þ

D0¼ ?2l a;b;τ

D0¼ 0 for a < b

Simulations performed under the null hypothesis of no

existence of threshold showed that under this hypothesis

the distribution of D’ may be approximated by a chi-

squared distribution with 3 degrees of freedom; thus

D’ may be compared to a chi-squared distribution with

3 degrees of freedom for testing the null hypothesis of

no threshold. The test is an unconditional significance

test of the step function represented by τ, a, b

compared to a constant probability of infection.

ð Þ þ 2l a0

ð Þfor a > b

Confidence interval for the threshold value

Confidence intervals for the threshold value may be

calculated by non-parametric bootstrapping following

standard methods [37]. Datasets were resampled 5000

times with replacement, and the lower and upper limits

of the 95% confidence interval for the threshold were

based on the 2.5 and the 97.5 percentiles of the

estimates of τ from each resampling.

Goodness-of-fit

Residuals defined by the differences between the observed

dichotomous outcomes and the modeled probability of

disease as in the a:b model are not normally distributed

and hence goodness-of-fit methods relying on normality

are inappropriate. Although Pearson and Chi-squared de-

viance residuals may be used for dichotomous outcomes,

when the number of discrete values of the model

predictors is large, such as for a continuous predictor like

titers, their distributions are not well approximated by

chi-squared distributions since the degrees of freedom

increases with the number of discrete values. In such

circumstances Hosmer and Lemeshow propose an ap-

proach in which the observed predictors are grouped into

10 groups defined by the deciles of the ordered

predictors, and goodness-of-fit is estimated by the

squared difference between observed and predicted infec-

tion rates in each group [38].

When applied to the a:b model, the goodness-of-fit

test statistic is

C ¼

X

10

g¼1

y:g? mg^ πg

mg^ πg 1 ? ^ πg

??2

??

where g indexes groups 1,...,10, y.g is the observed

number of cases in group g, mg is the number of

subjects in group g, and ^ πg is the predicted disease

probability in the group, i.e. ^ a or^b (or a weighted

averageif thegroup

Simulations show C to follow a chi-squared distribu-

tion with 8 degrees of freedom when the model is

true, so the goodness-of-fit may be quantified by the

probability in the upper tail of this distribution. The

test assesses whether the step function represented by

the a:b model is an appropriate representation of in-

fection or whether another relationship such as a grad-

ual one between titer and infection might be more

likely than a stepped relationship.

includes thethreshold).

Relative risk

The relative risk of disease above and below the

threshold may be a more readily interpretable measure

of the relevance of a fitted threshold. Note that relative

risk is not suitable as a criteria for selecting a value of

τ, since for different candidate values for τ the relative

risk declines from approximately 0.5 at low assay

values to near 0 at high values. However, having

selected τ, the relative risk quantifies the difference be-

tween those above the threshold and those below in

terms of the outcome of interest, namely probability of

disease. The relative risk is estimated by^b=^ a. An ap-

proximate 95% confidence interval for the relative risk

(conditional on the estimated value of τ) can be

obtained by parametric bootstrapping.

SAS statistical software was used for all analysis.

Chen et al. BMC Medical Research Methodology 2013, 13:29

http://www.biomedcentral.com/1471-2288/13/29

Page 4 of 10

Page 5

Datasets

The a:b model was applied to 15 datasets from four

studies. Briefly the datasets are:

? German pertussis datasets: eight assays for IgG or

IgA antibodies against pertussis toxin (PT), pertactin

(PRN), filamentous hemagluttinin (FHA) and

fimbriae (FIM) and occurrence of 44 cases of disease

in 1994 subjects from a sub-study of a pertussis

vaccine efficacy trial conducted in Germany between

1991 and 1994 [27]. IgG antibodies are a humoral

immune response whereas IgA antibodies are

responses at mucosal sites.

? Piedra/respiratory syncytial virus (RSV) datasets:

assays for antibody to RSV/A and RSV/B among

subjects presenting with acute respiratory symptoms

at a hospital in Texas, and subsequent disease

confirmation in 34 of 175 subjects [26].

? White/varicella dataset: varicella glycoprotein assay

for children vaccinated with varicella vaccine in

clinical trials conducted between 1987 and 1989, and

disease occurrence in 79 of 3459 subjects in

12 months of follow up [17].

? Swedish pertussis datasets: four assays (IgG antibodies

for PT, PRN, FHA, FIM) from subjects exposed to

pertussis by another household member and the

subsequent development of disease in 92 of 209

subjects, from a sub-study of a vaccine efficacy trial

conducted in Sweden between 1992 and 1995 [28].

Results

Threshold estimates, statistical significance and

confidence intervals

Figure 1 illustrates the application of the a:b model to

the 15 datasets where the model fit showing τ, a, b is

superposed on the observed data showing the infection

rates by titer value. Table 1 lists the values of each

threshold estimatedbyprofile

squares, their 95% confidence intervals (CIs) obtained by

bootstrap, p-values for test for threshold and goodness-

of-fit, and relative risk with CIs.

For 12 of 15 datasets least squares and profile likeli-

hood estimates of τ were the same while in the other

3 datasets (German pertussis PRN IgG, German per-

tussis FIM IgA, White/varicella) the least squares esti-

mate was lower than the profile likelihood estimate.

Thirteen of 15 thresholds found by the model were

highly statistically significant by the modified likelihood

ratio test with p-values <0.01, while two German pertus-

sis datasets for FHA IgA and PT IgA were not signifi-

cant at the 0.05 level.

There was considerable variability in the widths of the

95% confidence intervals when considered relative to the

range of the titers (Figure 1). In one instance, the

likelihood or least

German pertussis PT IgG data, the confidence interval

was notably narrow; in the cases of the RSV/A and

RSV/B datasets, the confidence intervals spanned a

large proportion of the range of the titers. When fitted

by profile likelihood, the point estimate of the thresh-

old for German pertussis PT IgG, PRN IgA, FIM IgA,

White/varicella and Swedish pertussis FIM datasets

was close to the upper limit of the 95% CI and close

to the lower limit for the German pertussis FIM IgG

dataset. A similar pattern was seen for some datasets

when fitted by least squares.

The upper and lower limits of the confidence intervals

found by profile likelihood were often found to be

greater than by least squares.

Goodness-of-fit

Using the ad-hoc criterion that a goodness-of-fit p-value

less than 0.20 represents a poor fit to the data, we

found that the a:b model did not fit well to three

datasets: White/varicella, German pertussis FHA IgG

and German pertussis FIM IgA. Visual inspection of

the plots in Figure 1 would suggest that protection

against varicella follows a gradually increasing protec-

tion rate by titer value rather than a stepwise relation-

ship, explaining the poor fit in this case. The German

pertussis FHA IgG and FIM IgA appear to follow a

similar gradual protection relationship. Another correlate

of protection which may not be well described by the a:b

model based on visual inspection of plots is RSV/B, but

this was associated with a goodness-of-fit p-value of

0.546. Apart from RSV/B, all other datasets which

were associated with goodness-of-fit p-values >0.20

could be visually confirmed to fit the stepwise shape

of the a:b model.

Relative risk

The relative risk estimate is dependent on the estimated

threshold, and offers an interpretation which is more fa-

miliar to the epidemiologist. The relative risk of disease

above the threshold compared to below ranged from 0

to 0.554 among the fifteen datasets. Except for 3 relative

risks with values near 0.5 and one near 0.4, all other

relative risks took values near 0.3 or less implying pro-

tection of 70% or better. Thus, in most cases, the

estimated threshold corresponds with the notion of an

absolute correlate to offer a high degree of protection.

Discussion

Despite the central importance of threshold values in

vaccines research and immunization policy, only the

Chang-Kohberger method [19,20] has been previously

proposed to estimate thresholds from assay values and

disease occurrence data, but its estimation requires

information on vaccinated and unvaccinated groups.

Chen et al. BMC Medical Research Methodology 2013, 13:29

http://www.biomedcentral.com/1471-2288/13/29

Page 5 of 10

Page 6

Figure 1 Illustration of fitted a:b model for the 15 datasets. Threshold values and 95% CIs for τ are superposed on the observed data

showing the infection rates by titer value. The numbers above each bar show the number of cases of disease and the number of subjects at

each binned assay value. Thresholds illustrated are those obtained by profile likelihood estimation. P-values refer to the modified likelihood ratio

test with small values indicating statistical significance. GoF refers to the p-value of the goodness-of-fit test with small values implying a poor fit

of the model to the data. RR is relative risk of infection above and below the threshold.

Chen et al. BMC Medical Research Methodology 2013, 13:29

http://www.biomedcentral.com/1471-2288/13/29

Page 6 of 10

Page 7

The a:b method provides a reliable, readily applicable

method for finding a threshold for paired data of the

form {yi,ti} for which previous models and associated

statistical testing were limited. The a:b model provides

the same estimate as the maximal chi-square method

[35] when least squares estimation is used.

The statistical criteria available for the evaluation of a

threshold estimated by the a:b model are confidence

interval width and location, goodness of fit, significance

testing and relative risk. A number of factors are likely

to influence the width of confidence intervals, including

the presence of a clear, high step in the data and the

number of subjects and cases of disease in the dataset.

Further, bootstrap confidence intervals based on the

candidate values of tau are affected by the density of dis-

tinct observed assay values in the region of the thresh-

old. This is a data limitation arising from the assay

technique which generates discrete rather than continu-

ous titer values, with lower densities (fewer distinct assay

values) tending to produce wider confidence intervals

and higher densities allowing the possibility of smaller

confidence intervals. The location of threshold point

estimates and upper and lower confidence limits in some

datasets suggested that profile likelihood estimates may

be higher and therefore more conservative, requiring

higher antibody titers to be achieved to conclude protec-

tion, compared to least squares estimates.

Goodness-of-fit p-value in some instances was clearly

consistent with the bar plots of the binned data while in

other cases this was less so, possibly due to discreteness in

the data resulting from small numbers of cases of disease.

Visual inspection of graphical representations of the data

might routinely supplement statistical assessments.

Because the estimated threshold itself does not imply

the degree of protection, relative risk aids in its interpret-

ation. If a threshold is to separate susceptible from

protected individuals, relative risk may be seen as a

measure of the degree of protection and can be employed

as one of the criteria for assessing the relevance of an

estimated threshold in addition to the p-value from the

test for significance. For example, the Swedish pertussis

FHA IgG result produced a p-value of 3.5×10−4but a

relative risk of 0.508, implying around 50% reduction in

risk, which may question the acceptability of the thresh-

old as higher protection is generally expected in vaccine

preventable disease.

Ideally, all assessment criteria would provide consist-

ent results in support of a threshold. However, instances

were noted where other conclusions might be warranted

even though some statistical assessments were promis-

ing. For example, for the White/varicella data, there is a

small confidence interval for the threshold, the p-value

for the threshold is highly significant and the relative

risk acceptable (close to 0.1) but the goodness-of-fit is

poor (p=0.085). It was found that that this data is better

fitted by a continuous scaled-logit model (p for

goodness-of-fit =0.999), suggesting that a relative rather

than absolute threshold may be appropriate.

The threshold in the a:b model is the titre value that

best separates the sample of patients into two groups

with different but constant infection rates, but this does

not require the ‘protected’ group to have a specified low

Table 1 Correlate of protection threshold values ^ τ estimated by a:b model and evaluation criteria for 15 immunological

datasets on pertussis, RSV and varicella

Dataset (cases of disease: subjects)

^ τ by profile likelihood

(95% CI)(95% CI)

^ τ by least-squaresp-value, test for

threshold†

6.0×10–11

3.2×10–11

4.1×10–9

9.1×10–10

p-value,

goodness-of-fit†

Relative risk†

(95% CI)

German pertussis FHA IgG (44:1988) 1.995 (1.185;18.13)1.995 (0.990;2.025)

0.114 0.093 (0.030;0.183)

German pertussis PT IgG (44:1987) 1.385 (0.965;1.390)1.385 (0.755;1.390)

0.798 0.055 (0.000;0.133)

German pertussis PRN IgG (44:1992)13.165 (1.375;29.31) 7.665 (0.855;13.17)

0.615 0.052 (0.000;0.141)

German pertussis FIM IgG (44:1986) 0.315 (0.305;4.500)0.315 (0.215;0.540)

0.284 0.111 (0.040;0.216)

German pertussis FHA IgA (44:1932) 0.385 (0.305;1.960)0.385 (0.315;1.960)0.3440.742 0.501 (0.267;1.237)

German pertussis PT IgA (44:1933) 1.785 (0.475;3.179)1.785 (0.415;4.064)0.497

1.4×10–3

1.3×10–4

2.0×10–3

2.7×10–3

<1.0×10–12

3.5×10–4

3.0×10–4

5.1×10–10

2.2×10–09

0.502 0.554 (0.181;1.120)

German pertussis PRN IgA (44:1968) 2.505 (0.760;2.510)2.505 (0.485;2.510)

0.346 0.000 ( − ; - )

German pertussis FIM IgA (44:1994) 3.385 (1.565;3.830)1.575 (1.030;3.825)

0.159 0.176 (0.037;0.375)

Piedra RSV/A (34:175)76.109 (5.657;608.9)76.109 (4.757;215.3)

0.9180.308 (0.163;0.544)

Piedra RSV/B (34:175)107.635 (8.000;1722) 107.635 (5.657;861.1)

0.5460.305 (0.169;0.548)

White/Varicella (79:3459) 5.011 (2.584;5.011)2.584 (1.311;5.011)

0.0850.098 (0.053;0.163)

Swedish pertussis FHA IgG (92:209)1.414 (0.707;6.481) 1.414 (0.707;6.481)

0.9660.508 (0.358;0.687)

Swedish pertussis PT IgG (92:209) 5.477 (1.414;15.49)5.477 (1.414;10.49)

0.9990.391 (0.199;0.614)

Swedish pertussis PRN IgG (92:209)5.950 (2.298;15.92) 5.950 (1.497;6.380)

0.9210.130 (0.030;0.270)

Swedish pertussis FIM IgG (92:209) 7.650 (1.249;7.846)4.225 (1.249;7.846)

0.7810.177 (0.056;0.325)

†for ^ τ found by profile likelihood.

Chen et al. BMC Medical Research Methodology 2013, 13:29

http://www.biomedcentral.com/1471-2288/13/29

Page 7 of 10

Page 8

probability of infection. It is therefore possible that the

protected group defined by the estimated threshold has

a high probability of infection, like 20% in the pertussis

PT IgG example, which could be deemed to be un-

acceptably high if one’s definition of a threshold requires

low risk of infection. Therefore, an additional criterion

that sets a maximally acceptable probability of infection

amongst the protected group could be considered in

addition to statistical tests when evaluating thresholds.

Although definitions of thresholds may differ, it is en-

couraging to note that others’ published estimates of

thresholds for these same datasets are not dissimilar to

estimates from the a:b model, suggesting consistency with

others’ notion of an acceptable threshold. For instance, a

previous analysis of the White/varicella data identified a

gp ELISA titer of 5 U/mL to indicate protection, which is

now reported to be an ‘approximate correlate of protec-

tion’ for varicella vaccines [39]. The estimate was consist-

ent with our profile likelihood estimate of the threshold of

5.011 (95% CI; 2.584; 5.011). For the Swedish pertussis

data, a putative threshold value of 5 units/mL for PRN,

FIM and PT were found to be associated with high protec-

tion [28]; subjects having all three had even higher protec-

tion. However, while the authors applied the same

putative threshold to all 3 pertussis components, we

estimated different values for each: 5.477 (95% CI;

1.414;15.49) for PT, 5.950 (95% CI; 2.298;15.92) for PRN

and 7.650 (95% CI; 1.249;7.846) for FIM. For the German

pertussis data, a regression tree approach found that a

threshold value of 7 units/mL for PRN IgG was most pre-

dictive of protection [23]. We estimated a threshold of

13.165 (95% CI; 1.375;29.31) with profile likelihood and

7.665 (95% CI; 0.855;13.17) using least squares. Amongst

the subset of subjects achieving 7 units/mL for PRN, those

who had 66 units/mL of PT IgG had even greater protec-

tion. Our estimated threshold for PT IgG using profile like-

lihood was 1.385 (95% CI; 0.965;1.390), but this figure is

not comparable to the previous figure of 66 unit/mL which

should be interpreted as a conditional threshold given that

protective PRN levels are achieved.

Because the a:b model assumes constant rates of infec-

tion on each side of the threshold, which may be a strong

assumption, we considered in supplementary analyses

more flexible models which allowed linear, quadratic or

logistic relationships on either side of the threshold.

However,these models

corresponding with the expectations of a correlate of

protection. For instance, a step-down of infection rate at

the threshold value and non-increasing rates of infection

on either side of the threshold were not always observed.

The a:b model was always consistent with these

expectations. In addition, visual examination of the pro-

file likelihood for these other models did not show sharp

peaks corresponding to the optimal threshold value, and

did not producefits

were associated with wider confidence intervals resulting

in greater uncertainty of the threshold value. In general

these more flexible models could not be relied upon to

consistently find a threshold which could be said to dif-

ferentiate protected from susceptible individuals.

The a:b model presented here does not require vaccin-

ation information to estimate a threshold. While this is

an advantage, it is also a weakness given that the a:b

model can provide only the first level of information in

the hierarchy of evidence to demonstrate a statistical

correlate of vaccine efficacy in the framework described

by Qin et al. [7]. To provide a higher level of evidence,

the a:b model could be developed to include a vaccin-

ation parameter and an associated test. Also, further de-

velopment could allow for multiple co-correlates in

which two or three threshold values are estimated simul-

taneously. This could have application to diseases like

pertussis where more than one antigen is necessary for

the fullest protection or for new vaccines that protect

against multiple serotypes of a disease, such as pneumo-

coccal infection or dengue. Further research might also

compare different statistical models for correlates of

protection – the a:b model, the method of Chang and

Kohberger [19-21], the scaled logit model [32-35], a lin-

ear trend model and logistic regression – and the

conclusions reached by each for levels of protection.

In order to investigate correlates of protection and

thresholds, there are also clinical and immunological

considerations. A correlate must include a clearly defined

clinical endpoint, whether protection is afforded against in-

fection, disease, severe disease, infectiousness, carriage or

other condition. For instance, it is thought that protection

against pneumococcal infection requires progressively

lower thresholds for protection against pneumococcal car-

riage, otitis media, pneumonia and invasive pneumococcal

infection [40]. Similarly, standardized laboratory assays and

tests for disease case confirmation are also needed but not

always feasible, which can potentially introduce bias in la-

boratory confirmed disease cases in some studies. An assay

must first be selected by immunologists and validated

according to immunological criteria – sensitivity, specifi-

city, reliability, and freedom from inter-technician variabil-

ity. It may be of interest to know whether the specific

immune response measured by the assay is responsible for

protection; statistical methods for causal inference have re-

cently been developed allowing an assay to be selected

which has been shown to be causally associated with

protection [41,42]. Other considerations include: host

factors in which the immune system changes throughout

life implying different immune response by age, temporal

immunological factors such as timing of measurement

and kinetics of the immune response, and population

factors given that observed thresholds may not be uni-

versally applicable to all settings. Thus, once a correlate of

Chen et al. BMC Medical Research Methodology 2013, 13:29

http://www.biomedcentral.com/1471-2288/13/29

Page 8 of 10

Page 9

protection or threshold is proposed, further discussions

with stakeholders are necessary to cover these disease-

specific considerations that the statistical methods alone

cannot address.

A final practical requirement is that datasets to iden-

tify immunological correlates of protection are essential.

Vaccine efficacy trials provide a clear opportunity to col-

lect data on the relationship between assay values for

candidate correlates of protection and disease occur-

rence; however, they are often sized inadequately to yield

convincing conclusions on correlates of protection. Typ-

ically trials are designed to capture 40–100 cases of dis-

ease to convincingly demonstrate adequate vaccine

efficacy against placebo [43-45], but such trials are gen-

erally underpowered for assessing correlates of protec-

tion. Incorporation of a correlate of protection objective

in clinical trials can incur substantial expense to the trial

as it would require additional bleeds in subjects after

they receive vaccine or placebo to observe their assay

values and before any significant number of disease

cases occur. Furthermore, more refined titer measures

(i.e. less discrete data) would require more serial

dilutions and greater blood volumes.

Conclusions

The a:b model together with the evaluation criteria

proposed provide a much-needed set of methods for the

estimation and assessment of thresholds values of im-

munological correlates of protection.

Additional file

Additional file 1: Supplementary information on estimating

equations for a:b model and on equivalence of Miller’s maximal chi-

square and least-square estimates of a:b model.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

All authors contributed to the formulation of the research question, made

methodological suggestions for consideration and evaluation by the group,

and contributed to the interpretation of the results. XC, FB and AD

performed the statistical calculations and KD and AD drafted the manuscript.

All authors read and approved the final version.

Acknowledgements

The authors wish to thank Dr. Lennart Gustafsson for making available the

Swedish household pertussis dataset, Dr. Pedro Piedra for making available

the RSV dataset, Dr. James Cherry and Herr Prof. Dr. Ulrich Heininger for

permission to use the German pertussis dataset, and Dr. C. Jo White for

assistance with the varicella dataset. Dr. Hexin Zhang and Dr. Liou Xu

provided suggestions which were incorporated into the work, for which we

are grateful. The authors also with to thank the two reviewers, whose

comments resulted in valuable improvements to the manuscript.

Author details

1Sanofi Pasteur, Beijing, China.2Sanofi Pasteur, Marcy L’Etoile, France.3United

Biosource Corporation, London, UK.4Statistical Center for HIV/AIDS Research

and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

5Current address: Amazon.com, Inc, Seattle, WA, USA.6Sanofi Pasteur,

Swiftwater, PA, USA.

Received: 16 September 2012 Accepted: 19 February 2013

Published: 1 March 2013

References

1. Siegrist CA, Plotkin SA, Orenstein W: The immunology of vaccintion. In

Vaccines. 5th edition. Offit PA: Elsevier; 2008:17–36.

2.

Advisory Committee for Immunization Practices (ACIP): ACIP Recommendations.

http://www.cdc.gov/vaccines/pubs/ACIP-list.htm.

3.World Health Organization, Department of Immunization, Vaccines and

Biologicals: Immunological basis for immunization series. http://www.who.int/

immunization/documents/immunological_basis_series/en.

4.Plotkin SA: Correlates of protection induced by vaccination. Clin Vaccine

Immunol 2010, 17(7):1055–1065.

5. Baylor N: Regulatory perspective: issues of correlates versus surrogates and implications

for licensure. Bamako, Mali: WHO Global Vaccine Research Forum conference

workshop on correlates of protection relevant to the African context; 2009.

http://www.who.int/vaccine_research/documents/WCP_Baylor_presentation.pdf.

6.

Grand Challenges in Global Health. http://www.grandchallenges.org/NewVaccines/

Challenges/LearnaboutImmunologicalResponses/Pages/default.aspx.

7.Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG: A framework for assessing

immunological correlates of protection in vaccine trials. J Infect Dis 2007,

196(9):1304–1312.

8. Gilbert PB, Qin L, Self SG: Evaluating a surrogate endpoint at three levels,

with application to vaccine development. Stat Med 2007, 27:4758–4778.

9.Plotkin SA, Gilbert PG: Nomenclature for immune correlates of protection

after vaccination. Clin Infect Dis 2012, 54(11):1615–1617.

10.Dunning A: Experimental designs and statistical methods for post-licensure

immunological correlates of protection. Washington DC: ASA Biopharmaceutical

Section FDA-Industry Statistics Workshop; 2011. http://www.amstat.org/meetings/

fdaworkshop/index.cfm?fuseaction=AbstractDetails&AbstractID=301569.

11.Chan I: Assessing the predictive value of immunological markers in vaccines.

Washington DC: ASA Biopharmaceutical Section FDA-Industry Statistics

Workshop; 2011. http://www.amstat.org/meetings/fdaworkshop/index.cfm?

fuseaction=AbstractDetails&AbstractID=301590.

12. Björkholm B, Böttiger M, Christenson B, Hagberg L: Antitoxin antibody

levels and the outcome of illness during an outbreak of diphtheria

among alcoholics. Scand J Infect Dis 1986, 18(3):235–239.

13.World Health Organization, Department of Immunization, Vaccines and Biologicals:

Immunological basis for immunization series. Module 2: Diptheria Update 2009.

http://whqlibdoc.who.int/publications/2009/9789241597869_eng.pdf.

14.Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR,

Orenstein WA: Measles antibody: reevaluation of protective titers. J Infect

Dis 1990, 162(5):1036–1042.

15.Neumann PW, Weber JM, Jessamine AG, O’Shaughnessy MV: Comparison

of measles antihemolysin test, enzyme-linked immunosorbent assay,

and hemagglutination inhibition test with neutralization test for

determination of immune status. J Clin Microbiol 1985, 22(2):296–298.

16.Goldschneider I, Gotschlich EC, Artenstein MS: Human immunity to the

meningococcus. II. Development of natural immunity. J Exp Med. 1969,

129(6):1327–1348.

17.White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, Patterson CM, Capra A,

Miller WJ, Krah DL, Provost PJ, Ellis RW, Calandra GB: Modified cases of

chickenpox after varicella vaccination: correlation of protection with

antibody response. Pediatr Infect Dis J 1992, 11:19–23.

18.Siber GR: Methods for estimating serological correlates of protection.

Dev Biol Stand 1997, 89:283–296.

19.Jódar L, Butler J, Carlone G, Dagan R, Goldblatt D, Käyhty H, Klugman K,

Plikaytis B, Siber G, Kohberger R, Chang I, Cherian T: Serological criteria for

evaluation and licensure of new pneumococcal conjugate vaccine

formulations for use in infants. Vaccine 2003, 21(23):3265–3272.

20.Siber GR, Chang I, Baker S, Fernsten P, O’Brien KL, Santosham M, Klugman KP, Madhi

SA, Paradiso P, Kohberger R: Estimating the protective concentration of anti-

pneumococcal capsular polysaccharide antibodies. Vaccine 2007, 25:3816–3826.

21.Advisory Committee on Immunization Practices: Licensure of a 13-valent

pneumococcal conjugate vaccine (PCV13) and recommendations for use

among children. MMWR Morb Mortal Wkly Rep 2010, 59(9):258–261.

22.Andrews N, Borrow R, Miller E: Validation of serological correlate of

protection for meningococcal C conjugate vaccine by using efficacy

Chen et al. BMC Medical Research Methodology 2013, 13:29

http://www.biomedcentral.com/1471-2288/13/29

Page 9 of 10

Page 10

estimates from postlicensure surveillance in England. Clin Diagn Lab

Immunol 2003, 10(5):780–786.

Cherry JD, Gornbein J, Heininger U, Stehr K: A search for serologic

correlates of immunity to Bordetella pertussis cough illnesses.

Vaccine 1998, 16(20):1901–1906.

Dagan R, Givon-Lavi N, Fraser D, Lipsitch M, Siber GR, Kohberger R: Serum

serotype-specific pneumococcal anticapsular immunoglobulin g

concentrations after immunization with a 9-valent conjugate

pneumococcal vaccine correlate with nasopharyngeal acquisition of

pneumococcus. J Infect Dis 2005, 192(3):367–376.

Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J: A controlled

trial of a two-component acellular, a five-component acellular, and a

whole-cell pertussis vaccine. N Engl J Med 1996, 334(6):349–355.

Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP: Correlates of

immunity to respiratory syncytial virus (RSV) associated-hospitalization:

establishment of minimum protective threshold levels of serum

neutralizing antibodies. Vaccine 2003, 21(24):3479–3482.

Stehr K, Cherry JD, Heininger U, Schmitt-Grohé S, Überall M, Laussucq S,

Eckhardt T, Meyer M, Engelhardt R, Christenson P, the Pertussis Vaccine

Study Group: A comparative efficacy trial in Germany in infants who

received either the Lederle/Takeda acellular pertussis component DTP

(DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT

vaccine. Pediatrics 1998, 101(1):1–11.

Storsaeter J, Hallander HO, Gustafsson L, Olin P: Levels of anti-pertussis

antibodies related to protection after household exposure to Bordetella

pertussis. Vaccine 1998, 16:1907–1916.

Rapola S, Jantti V, Eerola M, Makela PH, Kayhty H, Kilpi T: Anti-PsaA and the

risk of pneumococcal AOM and carriage. Vaccine 2003, 21:3608–3613.

Jokinen JT, Ahman H, Kilpi TM, Mäkelä PH, Käyhty H: Concentration of

antipneumococcal antibodies as a serological correlate of protection:

An application to acute otitis media. J Infect Dis 2004, 190:545–550.

Chan I, Li S, Matthews H, Chan C, Vessey R, Sadoff J, Heyse J: Use of

statistical models for evaluating antibody response as a correlate of

protection against varicella. Stat Med 2002, 21(22):3411–3430.

Dunning AJ: A model for immunological correlates of protection.

Stat Med 2006, 25:1485–1497.

Coudeville L, Bailleux F, Riche B, Megas F, André P, Ecochard R: Relationship

between haemagglutination-inhibiting antibody titres and clinical

protection against influenza: development and application of a bayesian

random-effects model. BMC Med Res Methodol 2010, 10(1):18.

Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T,

Tam JS, Rappaport R, Eldridge JH, Gruber WC: Correlation of cellular

immune responses with protection against culture-confirmed influenza

virus in young children. Clin Vaccine Immunol 2008, 15(7):1042–1053.

Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T,

Clemens R, Rappuoli R: Hemagglutination inhibition antibody titers as a

correlate of protection for inactivated influenza vaccines in children.

Pediatr Infect Dis J 2011, 30(12):1081–1085.

Miller R, Siegmund D: Maximally selected chi square statistics.

Biometrics 1982, 38:1011–1016.

Efron B, Tibshirani R: An Introduction to the Bootstrap. Boca Raton. Chapman

& Hall/CRC Press LLC; 1994.

Hosmer DW, Lemeshow S, Klar J: Goodness-of-fit testing for the multiple

logistic regression when the estimated probabilities are small. Biom J

1988, 30:911–924.

Gershon AA, Takahashi M, Seward J: Varicella Vaccine. In Vaccines. 5th

edition. Edited by Plotkin SA, Orenstein W. Offit PA: Elsevier; 2008:915–958.

Goldblatt D: Immunological perspective on correlates for bacterial polysaccharide vaccines:

responses, memory and assays. Bamako, Mali: WHO Global Vaccine Research Forum

conference workshop on correlates of protection relevant to the African context; 2009.

http://www.who.int/vaccine_research/documents/WCP_Goldblatt_presentation.pdf.

Follmann D: Augmented designs to assess immune response in vaccine

trials. Biometrics 2006, 62(4):1161–1169.

Wolfson J, Peter Gilbert PB: Statistical identifiability and the surrogate

endpoint problem. Biometrics 2010, 66:1153–1161.

Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell

J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R,

Edwards K: Efficacy, safety and immunogenicity of heptavalent pneumococcal

conjugate vaccine in children. Pediatr Infect Dis J 2000, 19(3):187–195.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

40.

41.

42.

43.

44.Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N,

Holmes S: Clinical efficacy of cell culture-derived and egg-derived

inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis

2010, 51(9):997–1004.

Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al: Safety and efficacy of

an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J

Med 2006, 354(1):11–22.

45.

doi:10.1186/1471-2288-13-29

Cite this article as: Chen et al.: A threshold method for immunological

correlates of protection. BMC Medical Research Methodology 2013 13:29.

Submit your next manuscript to BioMed Central

and take full advantage of:

• Convenient online submission

• Thorough peer review

• No space constraints or color figure charges

• Immediate publication on acceptance

• Inclusion in PubMed, CAS, Scopus and Google Scholar

• Research which is freely available for redistribution

Submit your manuscript at

www.biomedcentral.com/submit

Chen et al. BMC Medical Research Methodology 2013, 13:29

http://www.biomedcentral.com/1471-2288/13/29

Page 10 of 10